Meridian Bioscience (VIVO) Misses Q4 EPS by 2c

Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.13, $0.02 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $49 million versus the consensus estimate of $48.05 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• Goldman Regional Director in US Adjusts List of Top Names
• Nike beats quarterly estimates as tariff recovery boosts profit
• UBS Upgrades Hyundai Glovis Co Ltd (086280:KS) to Buy